Elicio Therapeutics, Inc. (ELTX)
1.49
-0.01
(-0.67%)
USD |
NASDAQ |
Nov 20, 09:48
Elicio Therapeutics Cash from Operations (Quarterly) : -10.36M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -10.36M |
| June 30, 2026 | -8.165M |
| March 31, 2026 | -11.64M |
| December 31, 2025 | -6.797M |
| September 30, 2025 | -11.09M |
| June 30, 2025 | -8.95M |
| March 31, 2025 | -10.12M |
| December 31, 2024 | -8.744M |
| September 30, 2024 | -7.274M |
| June 30, 2024 | -8.928M |
| March 31, 2024 | -12.12M |
| December 31, 2023 | -9.896M |
| September 30, 2023 | -5.184M |
| June 30, 2023 | -9.475M |
| Date | Value |
|---|---|
| March 31, 2023 | -8.139M |
| December 31, 2022 | -7.276M |
| September 30, 2022 | -5.386M |
| June 30, 2022 | 6.136M |
| March 31, 2022 | -15.65M |
| December 31, 2021 | -14.36M |
| September 30, 2021 | -15.20M |
| June 30, 2021 | -10.53M |
| March 31, 2021 | -12.55M |
| December 31, 2020 | 20.59M |
| September 30, 2020 | -21.94M |
| June 30, 2020 | -12.80M |
| March 31, 2020 | -8.733M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Lineage Cell Therapeutics, Inc. | -5.62M |
| Armata Pharmaceuticals, Inc. | -5.516M |
| Voyager Therapeutics, Inc. | -19.67M |
| Black Diamond Therapeutics, Inc. | -8.338M |
| Invivyd, Inc. | -32.11M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Financing (Quarterly) | 17.78M |
| Free Cash Flow | -36.99M |
| Free Cash Flow Per Share (Quarterly) | -0.3942 |
| Free Cash Flow to Equity (Quarterly) | -10.21M |
| Free Cash Flow to Firm (Quarterly) | -9.948M |
| Free Cash Flow Yield | -87.69% |